Mode
Text Size
Log in / Sign up

Backup ventilation timing after apnoea in extremely preterm infants on nCPAP

Backup ventilation timing after apnoea in extremely preterm infants on nCPAP
Photo by HH E / Unsplash
Key Takeaway
Consider that reducing apnoea duration before backup ventilation did not improve oxygen target time in extremely preterm infants in this small RCT.

This was a randomized cross-over trial in a single Level 3 neonatal intensive care unit. The population was 24 enrolled extremely preterm infants <28 weeks on nasal continuous positive airway pressure (nCPAP) with backup ventilation (BUV); 22 completed the study. The intervention was start of backup ventilation after 4 seconds of apnoea duration (AD 4), and the comparator was start after 16 seconds (AD 16).

The primary outcome was time spent within predefined oxygen saturation (SpO2) target (88%-95% or ≥88% with FiO2=0.21). There was no difference between AD 4 and AD 16: 66.9% vs 67.2% (p=0.88). The rate of BUV was significantly higher during AD 4, but absolute numbers and effect size were not reported.

Safety events were not reported, though 2 out of 24 infants did not complete the study. Key limitations include single-centre design, small sample size, and potential carryover effects from the cross-over design. The practice relevance is that reducing apnoea duration before backup ventilation did not improve time within SpO2 target in this population. Results show association, not causation for clinical outcomes, and certainty is limited by sample size and single-centre setting.

Study Details

Study typeRct
EvidenceLevel 2
Follow-up6.5 mo
PublishedApr 2026
View Original Abstract ↓
OBJECTIVE: Central apnoea due to immaturity of the respiratory drive constitutes the main cause of frequent and prolonged desaturations in extremely preterm (EPT) infants <28 weeks. We investigated the impact of varying the duration of apnoea before backup ventilation (BUV) on the measures of oxygenation in EPT infants during nasal continuous positive airway pressure (nCPAP) therapy. DESIGN: Single-centre randomised cross-over trial. SETTING: Level 3 neonatal intensive care unit. PATIENTS: 24 EPT infants on nCPAP with BUV. MAIN OUTCOME MEASURES: The primary outcome was the time spent within a predefined oxygen saturation (SpO) target (88%-95% or ≥88% with fraction of inspired oxygen (FiO) =0.21) during start of BUV after 4 s of apnoea duration (AD 4) or 16 s of apnoea duration (AD 16) RESULTS: The study was successfully completed in 22 children (median gestational age 24+5 weeks, birth weight 628 g, postnatal age 48 days). Mean time spent within the SpO target didn't differ between AD 4 and AD 16 (66.9% vs 67.2%, p=0.88). There were no differences in the time below or above the SpO target, prolonged (>30 s, >60 s, >120 s) and severe (<80%, <70%) episodes of hypoxaemias and cerebral tissue oxygenation. Mean FiO, mean airway pressure, transcutaneous carbon dioxide pressure, heart rate and respiratory frequency did not differ while the rate of BUV was significantly higher during AD 4. CONCLUSION: Reducing the time of apnoea until start of BUV didn't improve the time spent within the SpO target in respiratory unstable EPT infants. Our data demand intensified efforts to specify these settings of non-invasive respiratory support that better achieve this important clinical goal. TRIAL REGISTRATION NUMBER: DRKS00031911.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.